Sign Out
Patients who have the therapy of tegafur-gemestat-otastat potassium.
Patients who have less than 7 days of the finishing day of the therapy of tegafur-gemestat-otastat potassium.
Patients with a known hypersensitivity to fluorouracil.
Patients in a poor nutritional state, those with depressed bone marrow function, those with potentially serious infections.
Pregnant women, women who may become pregnant and nursing mother.
Patients with non-malignant tumor.
Continue with Google